|
- Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung . . .
We evaluated zongertinib in a multicohort, phase 1a–1b trial involving patients with advanced or metastatic HER2 -mutant NSCLC
- Targeting HER2 in cancer: The story of zongertinib
Zongertinib, our investigational HER2 tyrosine kinase inhibitor, is being developed as a potential oral treatment for people with NSCLC with a specific mutation in the HER2 gene
- Oral HER2-targeted Therapy Zongertinib Demonstrates Clinical Benefit in . . .
Zongertinib elicited durable responses in patients with advanced, previously treated non-small cell lung cancer that harbored a HER2 mutation, according to results presented at the AACR Annual Meeting 2025
- Boehringer eyes third quarter FDA verdict for oral HER2 drug
The FDA has started a priority review of Boehringer Ingelheim's small-molecule HER2 inhibitor zongertinib as a treatment for a form of lung cancer, setting up a decision later this year and
- Zongertinib Priority Review FDA non-small cell lung cancer | Boehringer . . .
Zongertinib (also known as BI 1810631) is an investigational, irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2) while sparing EGFR, thereby limiting associated toxicities
- Groundbreaking oncology research zongertinib | Boehringer Ingelheim
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is highly selective and being developed as a potential treatment for non-small cell lung cancer (NSCLC)
- HER2 TKI – zongertinib - InOncology – Boehringer Ingelheim
Learn about zongertinib, our investigational HER2 TKI, currently in clinical development for the treatment of solid tumors
- Zongertinib positive results non-small cell lung cancer | Boehringer . . .
Zongertinib is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations Zongertinib was designed to spare wild-type EGFR thereby mitigating associated toxicities
|
|
|